Enanta Pharmaceuticals (ENTA)
(Delayed Data from NSDQ)
$12.43 USD
+0.24 (1.97%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $12.37 -0.06 (-0.48%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
Enanta Pharmaceuticals, Inc. [ENTA]
Reports for Purchase
Showing records 41 - 60 ( 165 total )
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY2Q21 Update - Pipeline Remains Undervalued w/ Multiple Catalysts Ahead
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY2Q21 Update - Pipeline Remains Undervalued w/ Multiple Catalysts Ahead
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare- Please Join Our Virtual 33rd Annual ROTH Conference on March 15 - 17th
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY1Q21 Update - Many 2021 Catalysts and a Strong Balance Sheet to Boot
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Takeaways from Recent Management Call - Expect a Catalyst Rich 2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Takeaways from Recent Management Call - Expect a Catalyst Rich 2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Takeaways from Recent Management Call - Expect a Catalyst Rich 2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Large Pharma Is Active in NASH - Could GSK Be Planning to Enter the Space?
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY2020 Update - Expect Catalysts from Several Indications During 2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Earnings Preview - Model Adjustments. Increasing PT to $107
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Enanta Pharmaceuticals, Inc.
Industry: Medical - Drugs
Final Program for Our Fourth Annual Virtual NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E